

**SEARLE**

Research in the service of mankind

# QUARTERLY REPORT MARCH 2025



DELIVERING  
**EXCELLENCE**



# Contents

**02**

**Company  
Information**

**03**

**Directors' Review  
Report**

**06**

**Directors' Review  
Report (Urdu)**

**07**

**Unconsolidated  
Statement of  
Financial Position**

**08**

**Unconsolidated  
Statement of  
Profit or Loss  
and Other  
Comprehensive  
Income**

**09**

**Unconsolidated  
Statement of  
Changes in Equity**

# 10

Unconsolidated  
Statement of  
Cash Flows

# 11

Notes to the  
Unconsolidated  
Financial  
Statements

# 24

Consolidated  
Financial  
Statements



# Company Information

## Board of Directors

Mr. Adnan Asdar Ali	Chairman
Mr. Syed Nadeem Ahmed	Chief Executive Officer
Mr. Zubair Razzak Palwala	
Mr. Munis Abdullah	
Ms. Faiza Naeem	
Ms. Shaista Khaliq Rehman	
Mr. Muhammad Zubair Haider Shaikh	

## Board of Audit Committee

Ms. Shaista Khaliq Rehman	Chairperson
Mr. Adnan Asdar Ali	Member
Mr. Munis Abdullah	Member

## Board of HR & Remuneration Committee

Mr. Muhammad Zubair Haider Shaikh	Chairman
Ms. Shaista Khaliq Rehman	Member
Ms. Faiza Naeem	Member

## Chief Financial Officer

Mr. Mobeen Alam

## Company Secretary

Mr. Zubair Razzak Palwala

## Auditors

A. F. Ferguson & Co.

## Legal Advisors

Mohsin Tayebaly & Co.

## Bankers

Albaraka Bank (Pakistan) Limited  
Askari Bank Limited  
Bank Al Habib Limited  
Bank Alfalah Limited  
The Bank of Punjab  
Dubai Islamic Bank Pakistan Limited  
Faysal Bank Limited  
Habib Bank Limited  
Habib Metropolitan Bank Limited  
Meezan Bank Limited  
National Bank of Pakistan  
Soneri Bank Limited

## REGISTERED OFFICE

One IBL Centre, 2<sup>nd</sup> Floor, Plot # 1  
Block 7 & 8, D.M.C.H.S, Tipu Sultan  
Road Off Shahra-e-Faisal, Karachi

## SHARE REGISTRAR

CDC Share Registrar Services Limited  
Head Office, CDC House, 99-B, Block  
'B' S.M.C.H.S., Main Shahrah-e-Faisal  
Karachi - 74400

# Directors' Report to the Members

We are pleased to present the unconsolidated interim financial information of the company for the nine months ended March 31, 2025. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting'. The directors' report is prepared in accordance with section 227 of the Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

## Financial highlights

The company reported revenue of Rs 19.11 billion, with a gross profit margin of 50.3%, representing an increase of 2.4 percentage points compared to the same period last year. This improvement was mainly attributable to strategic price adjustments and a more favorable product mix.

Finance costs decreased significantly to Rs 1.72 billion from Rs 2.67 billion in the corresponding period last year. This reduction was primarily due to lower interest rates and the settlement of long-term borrowings.

During the third quarter, spanning January to March 2025, sales grew by 3% compared to the same period last year. Sales for the quarter reached Rs. 5.95 billion, up from Rs. 5.78 billion in the corresponding quarter of the previous year. The gross profit margin improved to 53% as compared to 49% in the same quarter last year. As a result, the company reported a profit after tax of Rs. 307.5 million, as against a loss of Rs. 109 million recorded in the corresponding quarter of the previous year.

On nine monthly basis, the company achieved a net profit of Rs 268.81 million, reflecting a growth of 142% compared to Rs 111.28 million in the prior year period.

Below is a summary of the financial results for the nine months ended March 31, 2025:

	Quarter ended		Nine months period ended	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
	(Rupees in thousand)			
Revenue from contracts with customers	5,957,034	5,786,361	19,114,796	19,109,412
Cost of sales	(2,816,533)	(2,948,884)	(9,503,922)	(9,961,288)
<b>Gross Profit</b>	<b>3,140,501</b>	<b>2,837,477</b>	<b>9,610,874</b>	<b>9,148,124</b>
Distribution costs	(1,795,957)	(1,736,582)	(5,190,065)	(5,143,213)
Administrative expenses	(852,614)	(340,270)	(1,614,010)	(1,085,980)
Other expenses	(6,281)	10,781	(34,382)	(31,186)
Other income	198,061	30,896	270,997	149,504
Impairment loss on investment in subsidiary	-	-	(927,463)	-
<b>Profit from operations</b>	<b>683,710</b>	<b>802,302</b>	<b>2,115,951</b>	<b>3,037,249</b>
Finance cost	(346,961)	(862,563)	(1,715,792)	(2,670,199)
<b>(Loss) / Profit before levies and income tax</b>	<b>336,749</b>	<b>(60,261)</b>	<b>400,159</b>	<b>367,050</b>
Levies – minimum tax and final tax	(42,766)	(21,540)	(55,088)	(31,182)
<b>(Loss) / Profit before income tax</b>	<b>293,983</b>	<b>(81,801)</b>	<b>345,071</b>	<b>335,868</b>
Taxation	13,560	(28,010)	(76,262)	(224,592)
<b>(Loss) / Profit after taxation</b>	<b>307,543</b>	<b>(109,811)</b>	<b>268,809</b>	<b>111,276</b>

## EARNINGS PER SHARE

Basic earnings per share after taxation for the period is Rs. 0.53 (March 2024: Rs. 0.22). There is no dilution effect on the basic earnings per share of the Company, as the Company had no convertible dilutive potential ordinary shares outstanding as at March 31, 2025.

## FUTURE OUTLOOK


Searle remains committed to expanding its footprint through organic growth, despite ongoing socio-economic and market challenges. Our proactive approach and decisive leadership enable us to navigate external uncertainties such as exchange rate fluctuations, inflation, and rising global costs. The recent regulatory approval of ADALIMUMAB, Pakistan's first locally manufactured biosimilar drug, marks a major milestone in our pursuit of innovation and our commitment to make high tech biological accessible to all.

We are well-positioned to capitalize on the recent price deregulation of non-essential drugs, enhancing cash flows and enabling new product launches. Additionally, declining interest rates are expected to boost profitability by reducing financing costs. With a strong pipeline of over 200 products, expansion into high-growth therapeutic areas, and increasing exports to GCC and CIS markets, Searle is poised for sustained growth and value creation. We thank our shareholders for their continued support as we advance toward a future of innovation and market leadership.

For and on behalf of the Board



**Syed Nadeem Ahmed**  
Chief Executive Officer



**Zubair Razzak Palwala**  
Director

Karachi: April 30, 2025

## فی حصص آمدنی

اس مدت کے لیے ٹیکس کے بعد فی شیئر بنیادی آمدنی 0.53 روپے ہے (مارچ 2024: 0.22 روپے)۔ کمپنی کی بنیادی فی حصص آمدنی پر کوئی کمی کا اثر نہیں پڑا، کیونکہ 31 مارچ 2025 تک کمپنی کے پاس کوئی قابل تبدیل یا مکمل طور پر کم کرنے والے عام حصص بقیہ نہیں تھے۔

## مستقبل کا منظر نامہ

سرل (Searle) کی توجہ سماجی، اقتصادی، سیاسی، اور ماحولیاتی چیلنجوں کو نبرد آزما ہوتے ہوئے، نامیاتی طور پر اور اسٹریٹجک حصول کے ذریعے ترقی پر مرکوز ہے۔ ہمارا فعال نقطہ نظر اور بروقت فیصلہ سازی کا عزم ہمیں بیرونی غیر یقینی صورتحال جیسے کہ شرح مبادلہ کے اتار چڑھاؤ، افراط زر کے دباؤ اور بڑھتی ہوئی عالمی قیمتوں سے نمٹنے کے لیے اچھی پوزیشن میں رکھتا ہے۔ ADALIMUMAB، پاکستان کی پہلی مقامی طور پر تیار کی جانے والی بائیوسیمیلر دوا کی منظوری کے ساتھ، ہم اپنی بائیو ٹیکنالوجی پیشکشوں کو سب کے لیے قابل رسائی بنانے کے ہمارے عزم میں ایک اہم سنگ میل کی نشاندہی کرتی ہے۔

ہم غیر ضروری ادویات کی حالیہ قیمتوں کو کنٹرول کرنے، نقدی کے بہاؤ کو بڑھانے اور نئی مصنوعات کے آغاز کو فعال کرنے کے لیے اچھی پوزیشن میں ہیں۔ مزید برآں، سود کی گرتی ہوئی شرحوں سے مالیاتی اخراجات کو کم کر کے منافع میں اضافے کی توقع ہے۔ 200 سے زیادہ مصنوعات کی ایک مضبوط رینج کے ساتھ، اعلیٰ ترقی کے علاج والے علاقوں میں توسیع، اور GCC اور CIS ماریکیٹوں میں بڑھتی ہوئی برآمدات کے ساتھ، سرل (Searle) پائیدار ترقی اور قدر پیدا کرنے کے لیے تیار ہے۔ جدت طرازی اور مارکیٹ کی قیادت کے مستقبل کی طرف بڑھتے ہوئے ہم اپنے شیئر ہولڈرز کی مسلسل حمایت کے لیے ان کا شکریہ ادا کرتے ہیں۔

بورڈ کے لیے اور اس کی جانب سے

(Signature)  
Saeed Ahmad

زیر ذائق پال والا  
ڈائریکٹر

(Signature)  
Saeed Ahmad

سید ندیم احمد  
چیف ایگزیکٹو آفیسر

کراچی: 30 اپریل 2025

## ڈائریکٹرز رپورٹ برائے حصص یافتگان

31 مارچ 2025 کو ختم ہونے والی سہ ماہی کے لیے کمپنی کی غیر متفقہ عبوری مالیاتی معلومات پیش کرتے ہوئے ہمیں خوشی ہو رہی ہے۔ یہ مالیاتی باتاات بین الاقوامی اکاؤنٹنگ اسٹینڈرڈ (IAS-34) عبوری مالیاتی رپورٹنگ (د) کے تقاضوں کے مطابق تیار کیے گئے ہیں۔ ڈائریکٹرز کی رپورٹ کمپنیز ایکٹ 2017 کے سیکشن 227 اور لسٹڈ کمپنیز (کوڈ آف کارپوریٹ گورننس) ریگولیشنز، 2019 کے باب XII کے مطابق تیار کی گئی ہے۔

## مالی جھلکیاں

کمپنی نے 50.3 فیصد کے مجموعی منافع کے مارجن کے ساتھ 19.11 ارب روپے کی آمدنی کی ہے، جو گزشتہ سال کی اسی مدت کے مقابلے میں 2.4 فیصد کے اضافے کی نمائندگی کرتا ہے۔ یہ بہتری بنیادی طور پر اسٹریٹجک قیمت کی ایڈجسٹمنٹ اور زیادہ سازگار پروڈکٹس سے منسوب تھی۔

مالیاتی اخراجات نمایاں طور پر کم ہو کر 1.72 ارب روپے ہو گئے جو گزشتہ سال کی اسی مدت میں 2.67 ارب روپے تھے۔ اس کی بنیادی وجہ کم شرح سود اور طویل مدتی قرضوں کی ادائیگی تھی۔

جنوری سے مارچ 2025 تک کے تیسرے سہ ماہی کے دوران، فروخت میں گزشتہ سال کی اسی مدت کے مقابلے میں 3 فیصد اضافہ ہوا۔ اس سہ ماہی کی فروخت 5.95 ارب روپے رہی، جو پچھلے سال کی اسی سہ ماہی میں 5.78 ارب روپے تھی۔ مجموعی منافع کا مارجن بہتر ہو کر 53 فیصد ہو گیا، جو کہ پچھلے سال کی اسی سہ ماہی میں 49 فیصد تھا۔ اس کے نتیجے میں، کمپنی نے ٹیکس کے بعد 307.5 ملین روپے کا منافع حاصل کیا، جبکہ گزشتہ سال کی اسی سہ ماہی میں 109 ملین روپے کا نقصان ریکارڈ کیا گیا تھا۔

نومہ کی بنیاد پر، کمپنی نے 268.81 ارب روپے کا خالص منافع حاصل کیا، جو پچھلے سال کی اسی مدت کے 111.28 ارب روپے کے مقابلے میں 142 فیصد کے اضافے کی عکاسی کرتا ہے۔

31 مارچ 2025 کو ختم ہونے والے نومہ کے مالیاتی نتائج کا خلاصہ درج ذیل ہے:

نومہ کی مدت مکمل ہونے پر		سہ ماہی کی مدت مکمل ہونے پر		
مارچ 31 2024	مارچ 31 2025	مارچ 31 2024	مارچ 31 2025	
(پاکستانی روپے ہزاروں میں)				
19,109,412	19,114,796	5,786,361	5,957,034	صارفین کے ساتھ معاہدوں سے حاصل ہونے والی آمدنی
(9,961,288)	(9,503,922)	(2,948,884)	(2,816,533)	فروخت کی لاگت
9,148,124	9,610,874	2,837,477	3,140,501	مجموعی منافع
(5,143,213)	(5,190,065)	(1,736,582)	(1,795,957)	ڈسٹریبوشن کے اخراجات
(1,085,980)	(1,614,010)	(340,270)	(852,614)	انتظامی اخراجات
(31,186)	(34,382)	10,781	(6,281)	دیگر اخراجات
149,504	270,997	30,896	198,061	دیگر آمدنی
-	(927,463)	-	-	ماتحت ادارے میں سرمایہ کاری پر نقصان
3,037,249	2,115,951	802,302	683,710	آپریٹنگز سے منافع
(2,670,199)	(1,715,792)	(862,563)	(346,961)	مالیاتی لاگت
367,050	400,159	(60,261)	336,749	لیویز اور انکم ٹیکس سے قبل منافع
(31,182)	(55,088)	(21,540)	(42,766)	لیویز-کم از کم ٹیکس اور حتمی ٹیکس
335,868	345,071	(81,801)	293,983	منافع قبل از ٹیکس
(224,592)	(76,262)	(28,010)	13,560	انکم ٹیکس کے اخراجات
111,276	268,809	(109,811)	307,543	منافع بعد از ٹیکس



# UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

As at March 31, 2025

		(Un-audited) March 31, 2025	(Audited) June 30, 2024
		----- (Rupees in '000) -----	
<b>ASSETS</b>	Note		
<b>Non-current assets</b>			
Property, plant and equipment	6	6,827,591	7,051,790
Right-of-use asset		43,045	50,430
Investment properties - at cost		2,826,126	2,885,863
Intangible assets		15,431	25,968
Deferred tax assets		1,354,119	1,272,018
Long-term investments - subsidiaries	7	9,666,718	9,666,718
Long-term loans		75	150
Long-term deposits		7,396	7,396
		<b>20,740,501</b>	<b>20,960,333</b>
<b>Current assets</b>			
Stock-in-trade		2,677,231	2,309,106
Trade receivables	8	10,225,220	10,705,822
Loans and advances	9	2,170,936	1,660,751
Trade deposits and short-term prepayments		302,526	203,685
Other receivables	10	5,226,318	1,037,379
Short-term investment - at amortised cost		100,000	100,000
Taxation - payments less provision		2,030,736	1,966,929
Tax refunds due from Government - Sales Tax		201,212	207,440
Cash and bank balances		176,738	120,437
		<b>23,110,917</b>	<b>18,311,549</b>
Investment in subsidiary held for sale		-	11,200,000
		<b>43,851,418</b>	<b>50,471,882</b>
<b>Total assets</b>			
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
<b>Share Capital</b>			
Issued, subscribed and paid-up capital		5,114,945	5,114,945
<b>Capital Reserves</b>			
Share premium		9,085,133	9,085,133
Revaluation surplus on property, plant and equipment		3,911,077	4,062,375
<b>Revenue reserves</b>			
General reserve		280,251	280,251
Unappropriated profit		10,972,332	10,552,225
<b>Total equity</b>		<b>29,363,738</b>	<b>29,094,929</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
Employee benefit obligations		52,167	57,838
Long-term borrowings	11	63,672	3,768,070
Lease liabilities		61,715	68,914
		<b>177,554</b>	<b>3,894,822</b>
<b>Current liabilities</b>			
Trade and other payables	12	6,523,017	7,673,501
Short-term borrowings	13	7,546,164	9,554,191
Contract liabilities		11,289	24,508
Unpaid dividend		182,800	183,072
Unclaimed dividend		37,068	37,071
Current portion of lease liabilities		9,788	9,788
		<b>14,310,126</b>	<b>17,482,131</b>
<b>Total liabilities</b>		<b>14,487,680</b>	<b>21,376,953</b>
<b>Contingencies and commitments</b>	14		
<b>Total equity and liabilities</b>		<b>43,851,418</b>	<b>50,471,882</b>

The annexed notes from 1 to 23 form an integral part of these condensed interim financial statements.

  
Chief Executive

  
Director

  
Chief Financial Officer

# UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the period ended March 31, 2025 - Unaudited

		Quarter ended		Nine months period ended	
		March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
Note ----- (Rupees in '000) -----					
Revenue from contracts with customers	15	5,957,034	5,786,361	19,114,796	19,109,412
Cost of sales		(2,816,533)	(2,948,884)	(9,503,922)	(9,961,288)
Gross profit		3,140,501	2,837,477	9,610,874	9,148,124
Distribution costs		(1,795,957)	(1,736,582)	(5,190,065)	(5,143,213)
Administrative expenses		(852,614)	(340,270)	(1,614,010)	(1,085,980)
Other expenses		(6,281)	10,781	(34,382)	(31,186)
Other income	16	198,061	30,896	270,997	149,504
Impairment loss on investment in a subsidiary		-	-	(927,463)	-
Profit from operations		683,710	802,302	2,115,951	3,037,249
Finance cost		(346,961)	(862,563)	(1,715,792)	(2,670,199)
Profit / (Loss) before levies and income tax		336,749	(60,261)	400,159	367,050
Levies - minimum tax and final tax		(42,766)	(21,540)	(55,088)	(31,182)
Profit / (Loss) before income tax		293,983	(81,801)	345,071	335,868
Income tax credit / (expense)		13,560	(28,010)	(76,262)	(224,592)
Profit / (Loss) for the period		307,543	(109,811)	268,809	111,276
Other comprehensive income		-	-	-	-
Total comprehensive income		307,543	(109,811)	268,809	111,276
			(Re-stated)		(Re-stated)
Earnings per share - basic and diluted	17	0.60	(0.21)	0.53	0.22

The annexed notes from 1 to 23 form an integral part of these condensed interim financial statements.

  
Chief Executive

  
Director

  
Chief Financial Officer

# UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY

For the period ended March 31, 2025 - Unaudited

	Issued, subscribed and paid-up capital	Advance received against issue of share capital	Capital reserve		Revenue reserves		Total reserves	Total
			Share premium	Revaluation surplus on Property, plant & equipment	General reserve	Unappropriated profits		
Balance as at July 01, 2023	3,900,659	-	6,049,419	3,717,069	280,251	13,721,361	23,768,100	27,668,759
Subscription of shares against right issue of share capital	1,214,286	-	3,035,714	-	-	(40,748)	2,994,966	4,209,252
Transfer of incremental depreciation for the period (net of deferred tax)	-	-	-	(124,152)	-	124,152	-	-
Total comprehensive income for the period	-	-	-	-	-	111,276	111,276	111,276
Balance as at March 31, 2024	<u>5,114,945</u>	<u>-</u>	<u>9,085,133</u>	<u>3,592,917</u>	<u>280,251</u>	<u>13,916,041</u>	<u>26,874,342</u>	<u>31,989,287</u>
<b>Balance as at July 01, 2024</b>	<b>5,114,945</b>	<b>-</b>	<b>9,085,133</b>	<b>4,062,375</b>	<b>280,251</b>	<b>10,552,225</b>	<b>23,979,984</b>	<b>29,094,929</b>
Transfer of incremental depreciation for the period (net of deferred tax)	-	-	-	(151,298)	-	151,298	-	-
Total comprehensive income for the period	-	-	-	-	-	268,809	268,809	268,809
<b>Balance as at March 31, 2025</b>	<b><u>5,114,945</u></b>	<b><u>-</u></b>	<b><u>9,085,133</u></b>	<b><u>3,911,077</u></b>	<b><u>280,251</u></b>	<b><u>10,972,332</u></b>	<b><u>24,248,793</u></b>	<b><u>29,363,738</u></b>

The annexed notes from 1 to 23 form an integral part of these condensed interim financial statements.

  
Chief Executive

  
Director

  
Chief Financial Officer

# UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS

For the period ended March 31, 2025 - Unaudited

		March 31 2025	March 31 2024
	Note	----- (Rupees in '000) -----	
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Cash generated from operations	18	1,616,210	8,678,470
Employees benefit obligations paid		(9,721)	(4,918)
Finance cost paid		(1,907,945)	(2,630,989)
Income taxes paid		(277,258)	(301,555)
Long-term loans		75	(62)
Net cash generated from operating activities		(578,639)	5,740,946
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Purchase of property, plant and equipment		(160,030)	(112,538)
Proceeds from disposal of property, plant and equipment		16,685	90
Addition to investment properties		(17,672)	(100,594)
Investment in subsidiaries		-	(7,250,407)
Proceeds from disposal of subsidiary		6,545,784	-
Net cash used in investing activities		6,384,768	(7,463,449)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Dividend paid		(275)	(749)
Repayment of long-term borrowings		(5,811,751)	(1,566,225)
Advance received against issue of share capital net of issuance cost		-	4,209,252
Payment against lease liabilities		(18,075)	(11,449)
Net cash from financing activities		(5,830,101)	2,630,829
<b>Net increase in cash and cash equivalents</b>		<b>(23,972)</b>	<b>908,326</b>
Cash and cash equivalents at the beginning of the period		(7,145,454)	(7,781,495)
<b>Cash and cash equivalents at the end of the period</b>	19	<b>(7,169,426)</b>	<b>(6,873,169)</b>

The annexed notes from 1 to 23 form an integral part of these condensed interim financial statements.

  
Chief Executive

  
Director

  
Chief Financial Officer

# Notes to the Unconsolidated Condensed Interim Financial Statements

## For the period ended March 31, 2025 - Unaudited

### 1. THE COMPANY AND ITS OPERATIONS

**1.1** The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017). Its shares are quoted on the Pakistan Stock Exchange Limited (PSX). The Company is principally engaged in the manufacture of pharmaceutical and other consumer products. The registered office of the Company is situated at One IBL Centre 2nd Floor, Plot No. 1, Block 7 & 8 Dehli Mercantile Muslim Cooperative Housing Society, Tipu Sultan Road Off Shahrah-e-Faisal, Karachi.

International Brands (Private) Limited is the Parent Company, which holds 50.25% (March 31, 2024: 54.49%) shareholding in the Company.

**1.2** Following are the subsidiary companies:

	Principal place of business	Effective %age of holding	
		March 31, 2025	June 30, 2024
<b>Listed Company</b>			
- IBL HealthCare Limited		74.19%	74.19%
<b>Unlisted Companies</b>			
- Searle Pharmaceuticals (Private) Limited	Pakistan	100.00%	100.00%
- Searle Laboratories (Private) Limited		100.00%	100.00%
- Searle Biosciences (Private) Limited		100.00%	100.00%
- IBL Future Technologies (Private) Limited		100.00%	100.00%
- Nextar Pharma (Private) Limited *		87.20%	87.20%
- Searle IV Solutions (Private) Limited		100.00%	-
- Stellar Ventures (Private) Limited		100.00%	-
- Mycart (Private) Limited *		50.00%	-
- IBL Frontier Markets (Private) Limited *		100.00%	-
- Prime Health (Private) Limited *		100.00%	-

\* Nextar Pharma (Private) Limited is the subsidiary of Searle Biosciences (Private) Limited being the indirect subsidiary of the Company.

\* Mycart (Private) Limited, IBL Frontier Markets (Private) Limited, and Prime Health (Private) Limited are the subsidiaries of Stellar Ventures (Private) Limited being the indirect subsidiaries of the Company.

**1.3** These unconsolidated condensed interim financial statements are separate financial statements of the Company in which investments in subsidiaries have been accounted for at cost less accumulated impairment losses, if any.

### 2. BASIS OF PREPARATION

#### 2.1 Statement of compliance

**2.1.1** These unconsolidated condensed interim financial statements of the Company have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprises of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and

# Notes to the Unconsolidated Condensed Interim Financial Statements

## For the period ended March 31, 2025 - Unaudited

- Provisions of and directives issued under the Companies Act, 2017

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

**2.1.2** These unconsolidated condensed interim financial statements does not include all the information required for full financial statements and should be read in conjunction with the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2024.

**2.1.3** The comparative unconsolidated condensed interim statement of financial position presented in these unconsolidated condensed interim financial statements have been extracted from the audited annual unconsolidated financial statements of the Company for the year ended June 30, 2024, whereas the comparative unconsolidated condensed interim statement of profit or loss and other comprehensive income, unconsolidated condensed interim statement of cash flows and unconsolidated condensed interim statement of changes in equity are extracted from the un-audited unconsolidated condensed interim financial statements for the period ended March 31, 2024.

### **2.2 Basis of measurement**

These condensed interim unconsolidated financial statements have been prepared under the historical cost convention except as stated otherwise and should be read in conjunction with the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2024.

### **2.3 Functional and presentation currency**

These condensed interim financial statements are presented in Pakistani Rupees which is also the Company's functional currency. All financial information presented in Pakistani Rupees has been rounded off to the nearest thousand Rupee except where stated otherwise.

## **3. MATERIAL ACCOUNTING INFORMATION AND POLICIES**

**3.1** The accounting policies and methods of computation adopted in the preparation of these unconsolidated condensed interim financial statements are the same as those applied in the preparation of the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2024.

### **3.2 Restatement**

The Institute of Chartered Accountant of Pakistan (ICAP) has withdrawn the Technical Release 27 "IAS 12, Income Taxes (Revised 2012)" and issued guidance - "IAS 12 Application Guidance on Accounting for Minimum Taxes and Final Taxes" via circular No. 07/2024 dated May 15 2024. The said guidance requires certain amounts of tax paid under minimum and final tax regime to be shown separately as a levy instead of showing it in current tax.

Accordingly, the impact has been incorporated in these condensed interim financial statements retrospectively in accordance with the requirement of International Accounting Standard (IAS 8) - 'Accounting Policies, Change in Accounting Estimates and Errors'. This requirement was initially applied in the unconsolidated financial statements of the Company for the year ended June 30, 2024. Accordingly the figures of prior period condensed interim financial statement for the period ended March 31, 2024 have been restated. There has been no effect on the condensed interim statement of financial position, the condensed interim statement of changes in equity, the condensed interim statement of cash flows and earnings per share as a result of this change.

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

### Effect on unconsolidated statement of profit or loss and other comprehensive income

	For the period ended March 31, 2025			For the period ended March 31, 2024		
	Had there been no change in accounting policy	Impact of change in accounting policy	After incorporating the effects of change in accounting policy	Had there been no change in accounting policy	Impact of change in accounting policy	After incorporating the effects of change in accounting policy
	----- (Rupees in '000) -----					
<b>Profit before income tax</b>	<b>400,159</b>	<b>(55,088)</b>	<b>345,071</b>	367,050	(31,182)	335,868
<b>Levies</b>	-	(55,088)	(55,088)	-	(31,182)	(31,182)
<b>Income tax - net</b>	<b>(131,350)</b>	<b>55,088</b>	<b>(76,262)</b>	(255,774)	31,182	(224,592)

### 3.3 Changes in accounting standards, interpretations and pronouncements

#### a) Standards and amendments to approved accounting standards that are effective

There are certain standards, amendments and interpretations to the accounting and reporting standards which are mandatory for the Company's annual accounting period which began on July 1, 2024. However, these do not have any significant impact on the Company's financial reporting.

#### b) Standards and amendments to approved accounting standards that are not yet effective

There are certain standards, amendments and interpretations to the accounting and reporting standards that will be mandatory for the Company's annual accounting periods beginning on or after July 1, 2025. However, these will not have any impact on the Company's financial reporting and, therefore, have not been disclosed in these unconsolidated condensed interim financial statements.

The following standard and amendment are not effective for the accounting periods beginning on or after 1 January 2024 and have not been early adopted by the Company:

#### Amendment to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments

These amendments:

- clarify the requirements for the timing of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system;
- clarify and add further guidance for assessing whether a financial asset meets the solely payments of principal and interest (SPPI) criterion;
- clarify the requirements for the timing of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system;
- add new disclosures for certain instruments with contractual terms that can change cash flows (such as some instruments with features linked to the achievement of environment, social and governance (ESG) targets); and
- make updates to the disclosures for equity instruments designated at Fair Value through Other Comprehensive Income (FVOCI).

The management is in process of assessing the impact of above changes.

### 4. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

The carrying values of all financial assets and liabilities reflected in these unconsolidated condensed interim financial statements approximate to their fair value.

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

### 5. ACCOUNTING ESTIMATES AND JUDGEMENTS AND FINANCIAL RISK MANAGEMENT

**5.1** The preparation of the unconsolidated condensed interim financial statements in conformity with accounting and reporting standards, as applicable in Pakistan, requires management to make judgements, estimates and assumptions that affect the application of the accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

**5.2** The significant judgements made by the management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited annual unconsolidated financial statements as at and for the year ended June 30, 2024.

**5.3** The Company's financial risk management objectives and policies are consistent with those disclosed in the audited annual unconsolidated financial statements for the year ended June 30, 2024.

(Unaudited)	(Audited)
March 31,	June 30,
2025	2024
------(Rupees in '000)-----	

### 6. PROPERTY, PLANT AND EQUIPMENT

Operating assets - note 6.1	<b>6,316,727</b>	6,634,953
Capital work-in-progress - at cost	<b>510,864</b>	416,837
	<b>6,827,591</b>	7,051,790

**6.1** Details of additions in operating assets including transfers from capital work-in-progress during the period are as follows:

	Additions (at cost)		Disposals (at net book value)	
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
------(Rupees in '000)-----				
Leasehold Land	<b>6,145</b>	4,817	-	-
Building on leasehold land	<b>22,194</b>	16,336	-	-
Plant and machinery	<b>8,036</b>	7,627	-	-
Furniture & fittings	<b>1,342</b>	185	-	-
Office equipment	<b>32,029</b>	15,567	-	(23)
	<b>69,746</b>	44,532	-	(23)



## Notes to the Unconsolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

		(Unaudited)	(Audited)
	Note	March 31, 2025	June 30, 2024
------(Rupees in '000)-----			
<b>7</b>	<b>INVESTMENT IN SUBSIDIARY HELD FOR SALE</b>		
	<b>Investment in subsidiary company</b>		
	Searle Pakistan Limited - at cost	16,400,000	16,400,000
	Less: Provision for impairment	(6,127,463)	(5,200,000)
		10,272,537	11,200,000
	Less: sale proceeds received partially	(6,545,784)	-
		3,726,753	11,200,000
	Classified as other receivable	(3,726,753)	-
	10	-	11,200,000

		(Unaudited)	(Audited)
	Note	March 31, 2025	June 30, 2024
------(Rupees in '000)-----			
<b>8</b>	<b>TRADE RECEIVABLES</b>		
	Considered good		
	- Due from related parties, unsecured	8,324,102	9,753,318
	- Export receivables - secured	975,786	420,577
	- others - unsecured	1,110,655	717,250
		10,410,543	10,891,145
	Less: allowance for expected credit losses	(185,323)	(185,323)
		10,225,220	10,705,822

## 9 LOANS AND ADVANCES

- 9.1** These include advances to Searle Biosciences (Private) Limited amounting to Rs. 857.09 million (June 30, 2024: Rs. 769.99 million), Searle IV Solutions (Private) Limited amounting to Rs. 468.16 million (June 30, 2024: Rs. 298.3 million), Prime Health (Private) Limited amounting to Rs. nil (June 30, 2024: Rs. 8.13 million) and Stellar Ventures (Private) Limited amounting to Rs. 168.1 million (June 30, 2024: Rs. 87.14 million), wholly owned subsidiaries. These are provided for the purpose of financial assistance and are settled in the ordinary course of business.

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

	Note	(Unaudited) March 31, 2025	(Audited) June 30, 2024
------(Rupees in '000)-----			
<b>10 OTHER RECEIVABLES</b>			
<b>Receivables from related parties</b>			
Due from subsidiary companies:			
IBL Healthcare Limited against:			
Expenses		3,435	-
Royalty		15,528	15,465
Rental income		3,607	-
Searle Biosciences (Private) Limited against:			
Facility Management Fee		220,000	220,000
Expenses		171,052	171,052
Searle IV Solutions (Private) Limited against Expenses		60,097	60,097
IBL Frontier Markets (Private) Limited against expenses		50,623	51,355
Nextar Pharma (Private) Limited against expenses		-	5,906
		524,342	523,875
Due from parent company			
International Brands (Private) Limited against:			
Expenses		13,896	776
Rental income		16,881	3,670
Group relief		58,040	58,040
		88,817	62,486
Due from associated companies			
IBL Operations (Private) Limited against:			
Expenses		2,461	5,450
Rental income		5,457	3,607
IBL Unisys (Private) Limited against:			
Rental income		4,311	135
Expenses		-	88,191
IBL Logistics (Private) Limited against rental income		-	1,692
Universal Ventures (Private) Limited against:			
Sale of subsidiary		86,452	86,452
Due from other related party:			
United Retail (SMC-Private) Limited against:			
Expenses		43,050	9,609
Universal Retail (Private) Limited against:			
Rental income		60,950	36,184
Expenses		206,570	142,736
		409,251	374,056
Surplus arising under retirement benefit fund		5,250	5,250
<b>Receivables from other than related parties</b>			
Searle Pakistan Limited against:			
Expenses		385,787	-
Rental income		5,685	-
Noventa Pharma (Private) Limited against:			
Sale of subsidiary	7	3,726,753	-
Others, considered good		80,433	71,712
		5,226,318	1,037,379

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

	(Unaudited) March 31, 2025	(Audited) June 30, 2024
------(Rupees in '000)-----		
<b>11. LONG-TERM BORROWINGS</b>		
Musharaka Facility - notes 11.1	-	3,695,769
Diminishing Musharika	63,672	72,301
	<b>63,672</b>	<b>3,768,070</b>

**11.1.** The Company has obtained a musharaka facility from Habib Bank Limited (Musharaka Agent) for a period of 7 years with a repayment grace period of two years. The Company is required to repay the amount of the loan in quarterly installments, starting from September 2022. However, on February 24, 2021, the Company has repaid the loan amounting to Rs. 800 million to its Musharaka agent. This facility carries a mark-up of three months KIBOR plus 1.35%.

**11.2.** The Company has repaid the entire loan on January 30, 2025 to meet the requirement of Share Purchase Agreement along with an early payment fee of Rs. 49.43 million.

	(Unaudited) March 31, 2025	(Audited) June 30, 2024
------(Rupees in '000)-----		
<b>12. TRADE AND OTHER PAYABLES</b>		
Creditors & accrued liabilities	4,146,526	4,233,802
Bills payable in foreign currency	1,667,219	2,108,270
Payable to related parties	107,637	619,959
Payable to provident fund	145,029	73,354
Accrued mark-up	238,508	453,519
Workers' Profit Participation Fund	21,836	15,018
Workers' Welfare Fund	43,625	35,328
Other liabilities	152,637	134,251
	<b>6,523,017</b>	<b>7,673,501</b>

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the preiod ended March 31, 2025 - Unaudited

	(Unaudited) March 31, 2025	(Audited) June 30, 2024
------(Rupees in '000)-----		
<b>13. SHORT-TERM BORROWINGS</b>		
<b>Secured borrowings</b>		
<b>Conventional</b>		
Running finance facility - note -13.1	1,284,992	1,293,150
<b>Islamic</b>		
Running Musharaka	6,061,172	5,972,741
Current portion of long-term borrowings - note -13.1.1	-	2,088,300
	6,061,172	8,061,041
	7,346,164	9,354,191
<b>Unsecured</b>		
Borrowing from IBL Future Technologies (Private) Limited - note 13.2	200,000	200,000
	7,546,164	9,554,191

**13.1** The Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 7,650 million (June 30, 2024: Rs. 7,650 million) which include financing facilities obtained under Islamic mode amounting to Rs. 6,061 million (June 30, 2024: Rs. 6,350 million). The arrangements are secured jointly by registered mortgage of Rs. 2,025 million (2024: Rs. 1,631.25 million) of immovable property together with joint pari passu charge on all current assets of the Company to the extent of Rs. 11,940 million (2024: Rs. 11,940 million).

**13.1.1** The rates of mark-up ranged between 12.59% to 14.59% (2024: 22.96% to 24.66%) per annum

**13.2** This represents interest free loan obtained from IBL Future Technologies (Private) Limited - wholly owned subsidiary and is repayable on demand.

## 14. CONTINGENCIES AND COMMITMENTS

### 14.1 Contingencies

There has been no significant change in the status of contingencies as reported in the note 30 of annual audited financial statements of the Company for the year ended June 30, 2024.

### 14.2 Commitments

The facility for opening letters of credit and guarantees as at March 31, 2025, amounted to Rs. 2,750 million (June 30, 2024: Rs. 2,750 million) of which the amount remaining unutilised as at period ended March 31, 2025, amounted to Rs. 918.98 million (June 30, 2024: Rs. 1,530.98 million).

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the preiod ended March 31, 2025 - Unaudited

	March 31, 2025	March 31, 2024
	------(Rupees in '000)-----	
<b>15. REVENUE FROM CONTRACTS WITH CUSTOMERS</b>		
Gross sales		
Local sale of goods	19,258,357	19,383,875
Export sales	2,125,731	1,819,917
	<u>21,384,088</u>	<u>21,203,792</u>
Toll manufacturing	2,408	2,146
	<u>21,386,496</u>	<u>21,205,938</u>
Sales tax	(175,541)	(40,645)
	<u>21,210,955</u>	<u>21,165,293</u>
Less:		
Trade discount	(1,417,869)	(1,172,456)
Sales return	(678,290)	(883,425)
	<u>(2,096,159)</u>	<u>(2,055,881)</u>
	<u>19,114,796</u>	<u>19,109,412</u>
<b>16. OTHER INCOME</b>		
<b>Income from financial assets - others</b>		
Interest Income from Term Finance Certificates	14,595	17,731
<b>Income from non - financial assets</b>		
Rental income from investment property	68,111	63,879
Gain on disposal of property, plant and equipment	16,685	67
Facility Management Fee - Searle Biosciences (Private) Limited	-	50,000
Interest Income on Loan - Searle Pakistan Limited	147,963	-
Scrap sales	22,803	17,827
Others	840	-
	<u>256,402</u>	<u>131,773</u>
	<u>270,997</u>	<u>149,504</u>
<b>17. BASIC AND DILUTED EARNINGS PER SHARE</b>		
Profit for the period (Rupees in thousands)	268,809	111,276
Weighted average number of outstanding shares at the end of period (in thousand) - Restated	511,494	511,494
		(Re-stated)
Basic and diluted earnings per share (Rupees)	0.53	0.22

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

	March 31, 2025	March 31, 2024
	------(Rupees in '000)-----	
<b>18. CASH GENERATED FROM OPERATIONS</b>		
Profit before levies and income tax	400,159	367,050
<b>Add adjustments for non-cash charges and other items</b>		
Depreciation	469,023	400,487
Gain on disposal of property, plant and equipment	(16,685)	(67)
Amortisation of intangible assets	10,536	10,875
Amortisation of transaction cost	19,053	12,636
Provision for retirement benefits obligation	4,050	4,050
Finance cost	1,692,934	2,661,072
Interest on lease liability	10,876	9,425
Impairment loss on investment in a subsidiary	927,463	-
Profit before working capital changes	3,517,409	3,465,528
<b>Effect on cash flow due to working capital changes</b>		
(Increase) / decrease in current assets		
Inventories	(368,125)	494,722
Trade receivables	480,602	1,274,122
Loans and advances	(510,185)	(445,909)
Trade deposits and short-term prepayments	(98,841)	5,041
Other receivables	(462,186)	3,549,272
Refund due from Government - sales tax - net	6,228	2,100
	(952,507)	4,879,348
Increase / (decrease) in current liabilities		
Trade and other payables	(935,473)	347,580
Contract liabilities	(13,219)	(13,986)
	(948,692)	333,594
Cash flows generated from operations	1,616,210	8,678,470
<b>19. CASH AND CASH EQUIVALENTS</b>		
Cash and bank balances	176,738	113,268
Running finance under markup arrangements - note 13.1	(7,346,164)	(6,986,437)
	(7,169,426)	(6,873,169)

## Notes to the Unconsolidated Condensed Interim Financial Statements

### For the period ended March 31, 2025 - Unaudited

#### 20. SEGMENT INFORMATION

Based on internal management reporting structure for the period, no reportable segments were identified that were of continuing significance for decision making.

#### 21. TRANSACTIONS WITH RELATED PARTIES

Disclosure of transactions between the Company and related parties:

The related parties include associated companies, staff retirement funds, directors, key management personnel and close family members of directors and key management personnel. The Company in the normal course of business carries out transactions with various related parties. The Company enters into transactions with related parties on the basis of mutually agreed terms. Significant transactions with related parties are as follows:

		March 31,	March 31,
Nature of relationship	Nature of transactions	2025	2024
----- (Rupees in '000) -----			
Parent company	- Corporate service charges	91,560	99,000
	- Rent income	14,896	13,345
	- Income from provision of amenities	11,435	10,723
	- Issuance of right shares	-	3,254,963
Subsidiaries	- Revenue	448,183	381,426
	- Purchase of consumables	970,656	441,259
	- Loan on material	28,922	27,691
	- Royalty	26,755	18,656
	- Advance against financial assistance	329,020	747,678
	- Reimbursement of expenses	166,704	95,827
	- Rent income	3,607	19,575
	- Income from Provision of Amenities	2,190	1,967
	- Management Fees	-	50,000
	- Markup income	12,963	-
	- Raw material issued	8,299	-
	- Others	881	4,956
Associated companies	- Revenue	14,285,710	16,366,510
	- Salaries and wages	22,246	14,240
	- Purchases	-	7,245
	- Carriage and duties	203,512	156,683
	- Discounts claimed	434,444	284,342
	- Rent expense	72,797	38,868
	- Rent income	34,068	32,032
	- Income from Provision of Amenities	118,461	85,833
	- Stock claims	488,114	434,330
	- Internet services	5,046	8,608
	- Donations	35,574	49,808
	- Incentives to field force staff	18,298	4,493
	- Repair & maintenance	1,784	2,504

## Notes to the Unconsolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

		March 31,	March 31,
Nature of relationship	Nature of transactions	2025	2024
------(Rupees in '000)-----			
	- Merchandise expense	11,594	29,802
	- Acquisition of subsidiaries	-	7,250,407
	- Reimbursement of expenses	33,861	-
	- Others	5,610	33,966
Staff retirement benefits			
	- Contributions to Provident Fund	176,729	159,752
	- Benefits paid	93,562	92,723
Key management employees compensation			
	- Salaries and other employee benefits	285,300	228,578
	- Contributions to Provident Fund	20,474	21,815

**21.1** The status of outstanding balances with related parties as at March 31, 2025 is included in the respective notes to the financial statements.

## 22. CORRESPONDING FIGURES

Corresponding figures have been reclassified and re-arranged in these financial statements, wherever necessary, to facilitate comparison and to confirm with presentation in the current period, having insignificant impact.

## 23. DATE OF AUTHORISATION FOR ISSUE

These unconsolidated condensed interim financial statements were approved and authorised for issue by the Board of Directors of the Company on April 30, 2025.

  
Chief Executive

  
Director

  
Chief Financial Officer





# Consolidated Financial Statements

- 25** Consolidated Directors' Report
- 28** Consolidated Directors' Report (Urdu)
- 29** Consolidated Statement of Financial Position
- 30** Consolidated Statement of Profit or Loss and Other Comprehensive Income
- 32** Consolidated Statement of Cash Flows
- 33** Consolidated Statement of Changes in Equity
- 34** Notes to the Consolidated Financial Statements

# Directors' Report to the Members

We are pleased to present the consolidated interim financial information of the Searle group for the nine months ended March 31, 2025. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting'. The directors' report is prepared in accordance with section 227 of the Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

## Financial highlights

For the nine months ended March 31, 2025, the Group reported consolidated revenue of Rs 22 billion, with a gross profit margin of 48.8%, representing a 2.7 percentage point increase compared to the same period last year. This improvement is primarily driven by strategic price revisions and a more favorable product mix.

During the period, the Group successfully completed the disposal of its subsidiary, Searle Pakistan Limited. Profit from continuing operations stood at Rs 926 million. In addition to the improved gross margin, a key contributor to profitability was a 35% reduction in finance costs, which declined to Rs 1.76 billion from Rs 2.69 billion in the corresponding period of the previous year.

A summary of the financial results for the nine months ended March 31, 2025, is presented below:

	Quarter ended		Nine months period ended	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
	(Rupees in thousand)			
Revenue from contracts with customers	7,000,873	6,689,125	21,995,735	22,280,424
Cost of sales	(3,448,382)	(3,569,245)	(11,250,892)	(11,988,771)
<b>Gross Profit</b>	<b>3,552,491</b>	<b>3,119,880</b>	<b>10,744,843</b>	<b>10,291,653</b>
Distribution costs	(2,158,790)	(2,013,796)	(6,133,582)	(6,012,094)
Administrative expenses	(989,451)	(523,334)	(1,887,007)	(1,387,381)
Other expenses	(6,281)	9,791	(34,382)	(32,176)
Other income	198,718	63,616	279,740	197,775
<b>Profit from operations</b>	<b>596,687</b>	<b>656,157</b>	<b>2,969,612</b>	<b>3,057,777</b>
Finance cost	(362,452)	(874,052)	(1,764,559)	(2,697,208)
<b>Profit / (Loss) before levies and income tax</b>	<b>234,235</b>	<b>(217,895)</b>	<b>1,205,053</b>	<b>360,569</b>
Levies – minimum tax and final tax	(49,978)	-	(79,924)	-
<b>Profit / (Loss) before income tax</b>	<b>184,257</b>	<b>(217,895)</b>	<b>1,125,129</b>	<b>360,569</b>
Taxation	(22,771)	(82,355)	(198,890)	(359,737)
<b>Profit / (Loss) from continuing operations</b>	<b>161,486</b>	<b>(300,250)</b>	<b>926,239</b>	<b>832</b>
Profit / (loss) from discontinued operations – net of tax	(515,362)	(304,315)	(1,210,762)	(596,873)
<b>(Loss) / Profit for the period</b>	<b>(353,876)</b>	<b>(604,565)</b>	<b>(284,523)</b>	<b>(596,041)</b>

## EARNINGS PER SHARE

Basic earnings per share after taxation for the period is Rs. (0.63) (March 2024: Rs. (1.15)). There is no dilution effect on the basic earnings per share of the group, as the group had no convertible dilutive potential ordinary shares outstanding as at March 31, 2025.

## FUTURE OUTLOOK


Searle group remains committed to expanding its footprint through organic growth, despite ongoing socio-economic and market challenges. Our proactive approach and decisive leadership enable us to navigate external uncertainties such as exchange rate fluctuations, inflation, and rising global costs. The recent regulatory approval of ADALIMUMAB, Pakistan's first locally manufactured biosimilar drug, marks a major milestone in our pursuit of innovation and our commitment to make high tech biological accessible to all.

We are well-positioned to capitalize on the recent price deregulation of non-essential drugs, enhancing cash flows and enabling new product launches. Additionally, declining interest rates are expected to boost profitability by reducing financing costs. With a strong pipeline of over 200 products, expansion into high-growth therapeutic areas, and increasing exports to GCC and CIS markets, Searle group is poised for sustained growth and value creation. We thank our shareholders for their continued support as we advance toward a future of innovation and market leadership.

For and on behalf of the Board



**Syed Nadeem Ahmed**  
Chief Executive Officer



**Zubair Palwala**  
Director

Karachi: April 30, 2025

## فی حصص آمدنی


اس مدت کے لیے ٹیکس کے بعد فی شیئر بنیادی آمدنی 0.63 روپے ہے (مارچ 2024: 1.15 روپے)۔ سرل گروپ کی بنیادی فی حصص آمدنی پر کوئی کمی کا اثر نہیں پڑا، کیونکہ 31 مارچ 2025 تک کمپنی کے پاس کوئی قابل تبدیل یا ممکنہ طور پر کم کرنے والے عام حصص بقیات نہیں تھے۔


## مستقبل کا منظر نامہ

سرل (Searle) گروپ کی توجہ سماجی، اقتصادی، سیاسی، اور ماحولیاتی چیلنجوں کو نبرد آزما ہوتے ہوئے، نامیاتی طور پر اور اسٹریٹجک حصول کے ذریعے ترقی پر مرکوز ہے۔ ہمارا فعال نقطہ نظر اور بروقت فیصلہ سازی کا عزم ہمیں بیرونی غیر یقینی صورتحال جیسے کہ شرح مبادلہ کے اتار چڑھاؤ، افراط زر کے دباؤ اور بڑھتی ہوئی عالمی قیمتوں سے نمٹنے کے لیے اچھی پوزیشن میں رکھتا ہے۔ ADALIMUMAB، پاکستان کی پہلی مقامی طور پر تیار کی جانے والی بائیوسیمیلر دوا کی منظوری کے ساتھ، ہم اپنی بائیو ٹیکنالوجی پیشکشوں کو سب کے لیے قابل رسائی بنانے کے ہمارے عزم میں ایک اہم سنگ میل کی نمائندگی کرتی ہے۔

ہم غیر ضروری ادویات کی حالیہ قیمتوں کو کنٹرول کرنے، نقدی کے بہاؤ کو بڑھانے اور نئی مصنوعات کے آغاز کو فعال کرنے کے لیے اچھی پوزیشن میں ہیں۔ مزید برآں، سود کی گرتی ہوئی شرحوں سے مالیاتی اخراجات کو کم کر کے منافع میں اضافے کی توقع ہے۔ 200 سے زیادہ مصنوعات کی ایک مضبوط رینج کے ساتھ، اعلیٰ ترقی کے علاج والے علاقوں میں توسیع، اور GCC اور CIS مارکیٹوں میں بڑھتی ہوئی برآمدات کے ساتھ، سرل (Searle) گروپ پائیدار ترقی اور قدر پیدا کرنے کے لیے تیار ہے۔ جدت طرازی اور مارکیٹ کی قیادت کے مستقبل کی طرف بڑھتے ہوئے ہم اپنے شیئر ہولڈرز کی مسلسل حمایت کے لیے ان کا شکریہ ادا کرتے ہیں۔

بورڈ کے لیے اور اس کی جانب سے

  
ذمیر رزاق پال والا  
ڈائریکٹر

  
سید نعیم احمد  
چیف ایگزیکٹو آفیسر

کراچی: 30 اپریل 2025

## ڈائریکٹرز رپورٹ برائے حصص یافتگان

31 مارچ 2025 کو ختم ہونے والی سہ ماہی کے لیے سرل گروپ کی غیر متفقہ عبوری مالیاتی معلومات پیش کرتے ہوئے ہمیں خوشی ہو رہی ہے۔ یہ مالیاتی بیانات بین الاقوامی اکاؤنٹنگ اسٹینڈرڈ (IAS-34) عبوری مالیاتی رپورٹنگ (د) کے تقاضوں کے مطابق تیار کیے گئے ہیں۔ ڈائریکٹرز کی رپورٹ کمپنیز ایکٹ 2017 کے سیکشن 227 اور لسٹڈ کمپنیز (کوڈ آف کارپوریٹ گورننس) ریگولیشنز، 2019 کے باب XII کے مطابق تیار کی گئی ہے۔

## مالی جھلکیاں

31 مارچ 2025 کو ختم ہونے والے نو ماہ کے دوران، گروپ نے مجموعی طور پر 22 ارب روپے کی آمدنی رپورٹ کی، جس میں مجموعی منافع 48.8% رہا جو گزشتہ سال کے اسی عرصے کے مقابلے میں 2.7 فیصد پوائنٹس کا اضافہ ظاہر کرتا ہے۔ یہ بہتری بنیادی طور پر حکمت عملی کے تحت قیمتوں میں تبدیلی اور زیادہ سازگار مصنوعات کے مرکب کی وجہ سے آئی ہے۔

اس مدت کے دوران گروپ نے اپنی ذیلی کمپنی سرل پاکستان لمیٹڈ کی فروخت کا میابی کے مکمل کی۔ جاری آپریشنز سے منافع 9.26 ملین روپے رہا بہتر مجموعی منافع کے علاوہ، منافعت میں اہم کردار مالی اخراجات میں 35% کمی کا تھا، جو پچھلے سال کے اسی عرصے میں 2.69 ارب روپے سے کم ہو کر 1.76 ارب روپے تک پہنچ گیا۔

31 مارچ 2025 کو ختم ہونے والے نو ماہ کے مالیاتی نتائج کا خلاصہ درج ذیل ہے:

مارچ 2025 31	مارچ 2024 31	مارچ 2025 31	مارچ 2024 31
سہ ماہی کی مدت مکمل ہونے پر	نوامہ کی مدت مکمل ہونے پر		
مارچ 2025 31	مارچ 2024 31	مارچ 2025 31	مارچ 2024 31
(پاکستانی روپے ہزاروں میں)			
7,000,873	6,689,125	21,995,735	22,280,424
(3,448,382)	(3,569,245)	(11,250,892)	(11,988,771)
<b>3,552,491</b>	<b>3,119,880</b>	<b>10,744,843</b>	<b>10,291,653</b>
(2,158,790)	(2,013,796)	(6,133,582)	(6,012,094)
(989,451)	(523,334)	(1,887,007)	(1,387,381)
(6,281)	9,791	(34,382)	(32,176)
198,718	63,616	279,740	197,775
<b>596,687</b>	<b>656,157</b>	<b>2,969,612</b>	<b>3,057,777</b>
(362,452)	(874,052)	(1,764,559)	(2,697,208)
<b>234,235</b>	<b>(217,895)</b>	<b>1,205,053</b>	<b>360,569</b>
(49,978)	-	(79,924)	-
<b>184,257</b>	<b>(217,895)</b>	<b>1,125,129</b>	<b>360,569</b>
(22,771)	(82,355)	(198,890)	(359,737)
<b>161,486</b>	<b>(300,250)</b>	<b>926,239</b>	<b>832</b>
(515,362)	(304,315)	(1,210,762)	(596,873)
<b>(353,876)</b>	<b>(604,565)</b>	<b>(284,523)</b>	<b>(596,041)</b>

# CONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

As at March 31, 2025

		(Un-audited) March 31, 2025	(Audited) June 30, 2025
ASSETS		------(Rupees in '000)-----	
Non-current assets			
Property, plant and equipment	7	10,183,273	10,396,016
Right-of-use asset	8	48,656	63,982
Investment properties		6,117,870	6,177,607
Intangibles	9	4,010,082	4,625,119
Long-term loans and advances		75	150
Long-term deposits		10,824	10,824
Deferred tax asset		2,066,310	1,984,209
		22,437,090	23,257,907
Current assets			
Inventories		4,022,585	3,451,526
Trade Receivables	10	12,415,731	12,471,522
Loans and advances	11	986,144	673,796
Trade deposits and short-term prepayments		391,500	250,194
Other receivables	12	5,456,970	857,810
Short-term investment at amortised cost		100,000	100,000
Taxation - payments less provision		2,099,359	2,067,031
Tax refunds due from government - Sales tax		207,634	224,769
Cash and bank balances		277,563	302,839
		25,957,486	20,399,487
Assets classified as held for sale		-	19,903,375
Total assets		48,394,576	63,560,769
EQUITY AND LIABILITIES			
EQUITY			
Share capital		5,114,945	5,114,945
Share premium		9,085,133	9,085,133
Unappropriated profit		10,907,431	12,027,381
General reserve		280,251	280,251
Revaluation surplus on property, plant and equipment		5,872,215	6,023,513
Attributable to owners of		31,259,975	32,531,223
The Searle Company Limited - Holding Company		770,911	1,913,774
Non-controlling interests		32,030,886	34,444,997
LIABILITIES			
Non-current liabilities			
Long-term borrowings	13	63,586	3,768,070
Employee benefit obligations		65,163	57,838
Long term lease liability		64,692	71,891
		193,441	3,897,799
Current liabilities			
Trade and other payables	14	7,812,088	8,398,648
Short-term borrowings	15	7,772,405	7,296,569
Current portion of long-term borrowings		-	2,088,300
Contract liabilities		334,826	58,863
Unpaid dividend		196,835	197,224
Unclaimed dividend		44,127	44,176
Current portion of long-term lease liability		9,968	19,691
		16,170,249	18,103,471
Liabilities directly associated with assets classified as held for sale		-	7,114,502
Total liabilities		16,363,690	29,115,772
Contingencies and commitments			
	16		
Total equity and liabilities		48,394,576	63,560,769

The annexed notes from 1 to 25 form an integral part of these consolidated condensed interim financial statements

  
Chief Executive

  
Director

  
Chief Financial Officer

# CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the period ended March 31, 2025 - Unaudited

	Note	Quarter Ended		Nine months period ended	
		March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
----- (Rupees in '000) -----					
Revenue from contract with customers	17	7,000,873	6,689,125	21,995,735	22,280,424
Cost of sales		(3,448,382)	(3,569,245)	(11,250,892)	(11,988,771)
Gross profit		3,552,491	3,119,880	10,744,843	10,291,653
Distribution costs		(2,158,790)	(2,013,796)	(6,133,582)	(6,012,094)
Administrative expenses		(989,451)	(523,334)	(1,887,007)	(1,387,381)
Other operating expenses		(6,281)	9,791	(34,382)	(32,176)
Other income	18	198,718	63,616	279,740	197,775
Profit from operations		596,687	656,157	2,969,612	3,057,777
Finance cost		(362,452)	(874,052)	(1,764,559)	(2,697,208)
Profit / (loss) before levies and income tax		234,235	(217,895)	1,205,053	360,569
Levies - minimum tax and final tax		(49,978)	-	(79,924)	-
Profit / (loss) before income tax		184,257	(217,895)	1,125,129	360,569
Income tax expense		(22,771)	(82,355)	(198,890)	(359,737)
Profit / (loss) from continuing operations		161,486	(300,250)	926,239	832
Discontinued operations:					
Loss from discontinued operations – net of tax		(515,362)	(304,315)	(1,210,762)	(596,873)
Loss for the period		(353,876)	(604,565)	(284,523)	(596,041)
(Loss) / profit is attributable to:					
Owners of the Parent Company - continuing operations		156,500	(328,825)	911,548	(49,899)
Owners of the Parent Company - discontinued operations		(516,047)	(275,740)	(1,233,238)	(540,827)
		(359,547)	(604,565)	(321,690)	(590,726)
Non-controlling interests - continuing operations		4,986	28,575	14,691	50,731
Non-controlling interests - discontinued operations		685	(28,575)	22,476	(56,046)
		5,671	(20,797)	37,167	(5,315)
Basic & diluted earnings per share					
From continuing operations		0.31	(0.64)	1.78	(0.10)
From discontinued operations	19	(1.01)	(0.54)	(2.41)	(1.05)
		(0.70)	(1.18)	(0.63)	(1.15)

The annexed notes from 1 to 25 form an integral part of these consolidated condensed interim financial statements

  
Chief Executive

  
Director

  
Chief Financial Officer



# CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the period ended March 31, 2025 - Unaudited

	Quarter Ended		Nine months period ended	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
Note -----	(Rupees in '000)-----			
Loss for the period	(353,876)	(604,565)	(284,523)	(596,041)
<b>Other comprehensive loss:</b>				
Items that will not be reclassified subsequently to profit or loss				
Surplus on revaluation of property, plant and equipment asset classified as held for sale - net of deferred tax	(596,468)	-	(596,468)	-
<b>Total comprehensive loss for the period</b>	<b>(950,344)</b>	<b>(604,565)</b>	<b>(880,991)</b>	<b>(596,041)</b>
<b>Total comprehensive loss for the period is attributable to:</b>				
Owners of the Parent Company	(956,015)	(869,652)	(918,158)	(590,726)
Non-controlling interests	5,671	265,087	37,167	(5,315)
	<b>(950,344)</b>	<b>(604,565)</b>	<b>(880,991)</b>	<b>(596,041)</b>
<b>Total comprehensive income / (loss) attributable to owners of the Parent arise from:</b>				
From continuing operations	156,500	(72,055)	911,548	(49,899)
From discontinued operations	(1,112,515)	(797,597)	(1,829,706)	(540,827)
	<b>(956,015)</b>	<b>(869,652)</b>	<b>(918,158)</b>	<b>(590,726)</b>

The annexed notes from 1 to 25 form an integral part of these consolidated condensed interim financial statements

  
Chief Executive

  
Director

  
Chief Financial Officer

# CONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS

For the period ended March 31, 2025 - Unaudited

		March 31, 2025	March 31, 2024
	Note	----- (Rupees in '000) -----	
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Cash generated from operations	20	1,572,656	10,991,460
Employee benefit obligations paid		(841)	688
Finance cost paid		(2,358,508)	(3,144,157)
Income tax paid		(530,998)	(760,985)
Interest income received		5,505	420
(Increase) / decrease in long-term deposits		-	(2,379)
Lease rentals paid		(23,034)	(12,583)
Decrease / (increase) in long-term loans and advances		894	(62)
Net cash generated from operating activities		(1,334,326)	7,072,402
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Purchase of property, plant and equipment		(271,331)	(326,749)
Acquisition of subsidiaries - net		-	(7,265,291)
Sale proceeds on disposal of property, plant and equipment		35	1,599
Additions to investment properties		(17,672)	(202,131)
Net cash inflow against disposal of subsidiary companies		8,855,604	-
Net cash used in investing activities		8,566,636	(7,792,572)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Dividend paid		(438)	42,215
(Repayment) / Proceeds of borrowings		(5,811,208)	(1,566,225)
Advance received against issue of share capital net of issuance cost		-	4,209,252
Net cash generated from / (used in) financing activities		(5,811,646)	2,685,242
<b>Net increase in cash and cash equivalents</b>		<b>1,420,664</b>	<b>1,965,072</b>
Cash and cash equivalents at beginning of the period		(8,915,506)	(11,424,337)
<b>Cash and cash equivalents at end of the period</b>	21	<b>(7,494,842)</b>	<b>(9,459,265)</b>

The annexed notes from 1 to 25 form an integral part of these consolidated condensed interim financial statements

  
Chief Executive

  
Director

  
Chief Financial Officer

# CONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY

For the period ended March 31, 2025 - Unaudited

	Capital reserves			Revenue reserves				
	Share capital	Share premium account	Revaluation surplus on Property, plant & equipment	General reserve	Unappropriated profits	Sub-Total reserves	Non-Controlling interest	Total
	(Rupees in '000)							
Balance as at July 01, 2023	3,900,659	6,049,419	5,568,389	280,251	14,143,280	26,041,339	1,734,434	31,676,432
Total comprehensive loss for the period								
- Loss after tax	-	-	-	-	(590,726)	(590,726)	(5,315)	(596,041)
- Other comprehensive loss - net of tax	-	-	-	-	-	-	-	-
	-	-	-	-	(590,726)	(590,726)	(5,315)	(596,041)

## Transactions with owners

Issuance cost against rights issue	1,214,286	3,035,714	-	-	(40,748)	2,994,966	-	4,209,252
Acquisition of subsidiary	-	-	-	-	-	-	(165,070)	(165,070)
Non-redeemable convertible loan - note 13	-	-	-	-	-	-	361,773	361,773
	1,214,286	3,035,714	-	-	(40,748)	2,994,966	196,703	4,405,955
Transfer of incremental depreciation - net of deferred tax	-	-	(124,152)	-	124,152	-	-	-
Balance as at March 31, 2024	5,114,945	9,085,133	5,444,237	280,251	13,635,958	28,445,579	1,925,822	35,486,346
<b>Balance as at July 01, 2024</b>	<b>5,114,945</b>	<b>9,085,133</b>	<b>6,023,513</b>	<b>280,251</b>	<b>12,027,381</b>	<b>27,416,278</b>	<b>1,913,774</b>	<b>34,444,997</b>

## Total comprehensive loss for the period

- Loss after tax	-	-	-	-	(321,690)	(321,690)	37,167	(284,523)
- Other comprehensive loss - net of tax	-	-	-	-	(596,468)	(596,468)	-	(596,468)
	-	-	-	-	(918,158)	(918,158)	37,167	(880,991)

## Transactions with owners

Disposal of subsidiary	-	-	-	-	(353,090)	(353,090)	(1,180,030)	(1,533,120)
	-	-	-	-	(353,090)	(353,090)	(1,180,030)	(1,533,120)
Transfer of incremental depreciation - net of deferred tax	-	-	(151,298)	-	151,298	-	-	-
<b>Balance as at March 31, 2025</b>	<b>5,114,945</b>	<b>9,085,133</b>	<b>5,872,215</b>	<b>280,251</b>	<b>10,907,431</b>	<b>26,145,030</b>	<b>770,911</b>	<b>32,030,886</b>

The annexed notes from 1 to 25 form an integral part of these consolidated condensed interim financial statements

  
Chief Executive

  
Director

  
Chief Financial Officer

# Notes to the Consolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

## 1. LEGAL STATUS AND OPERATIONS

- 1.1** The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017). Its shares are quoted on the Pakistan Stock Exchange Limited (PSX). The Company is principally engaged in the manufacture of pharmaceutical and other consumer products. The registered office of the Company is situated at One IBL Centre 2nd Floor, Plot No. 1, Block 7 & 8 Dehli Mercantile Muslim Cooperative Housing Society, Tipu Sultan Road Off Shahrah-e-Faisal, Karachi.

International Brands (Private) Limited is the Parent Company, which holds 50.25% (March 31, 2024: 54.49%) shareholding in the Company.

Following are the subsidiary companies:

	Principal place of business	Percentage of effective holding	
		March 31, 2025 (Unaudited)	June 30, 2024 (Audited)
<b>Listed Company</b>			
- IBL HealthCare Limited		74.19%	74.19%
<b>Unlisted Companies</b>			
- Searle Pharmaceuticals (Private) Limited	Pakistan	100.00%	100.00%
- Searle Laboratories (Private) Limited		100.00%	100.00%
- Searle Biosciences (Private) Limited		100.00%	100.00%
- IBL Future Technologies (Private) Limited		100.00%	100.00%
- Searle IV Solutions (Private) Limited		100.00%	-
- Stellar Ventures (Private) Limited		100.00%	-
- IBL Frontier Markets (Private) Limited *		100.00%	-
- Prime Health (Private) Limited *		100.00%	-
- Mycart (Private) Limited *		50.00%	-
- Nextar Pharma (Private) Limited *		87.20%	87.20%

\* Nextar Pharma (Private) Limited is the subsidiary of Searle Biosciences (Private) Limited being the indirect subsidiary of the Parent Company.

\* MyCart (Private) Limited, IBL Frontier Markets (Private) Limited and Prime Health MyCart (Private) Limited are the subsidiaries of Stellar Ventures (Private) Limited being the indirect subsidiary of the Parent Company.

## 2. BASIS OF PREPARATION

### 2.1 Statement of compliance

- 2.1.1** These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

# Notes to the Consolidated Condensed Interim Financial Statements

## For the period ended March 31, 2025 - Unaudited

**2.1.2** These consolidated condensed interim financial statements does not include all the information required for full financial statements and should be read in conjunction with the audited annual Consolidated financial statements of the Company as at and for the year ended June 30, 2024.

**2.1.3** The comparative consolidated condensed interim statement of financial position presented in these unconsolidated condensed interim financial statements have been extracted from the audited annual unconsolidated financial statements of the Company for the year ended June 30, 2024, whereas the comparative unconsolidated condensed interim statement of profit or loss and other comprehensive income, unconsolidated condensed interim statement of cash flows and unconsolidated condensed interim statement of changes in equity are extracted from the un-audited unconsolidated condensed interim financial statements for the period ended March 31, 2024.

### **2.2 Basis of measurement**

These condensed interim Consolidated financial statements have been prepared under the historical cost convention except as stated otherwise and should be read in conjunction with the audited annual Consolidated financial statements of the Company for the year ended June 30, 2024.

### **2.3 Functional and presentation currency**

These condensed interim Consolidated financial statements are presented in Pakistani Rupees which is also the Company's functional currency. All financial information presented in Pakistani Rupees has been rounded off to the nearest thousand Rupee except where stated otherwise.

## **3. MATERIAL ACCOUNTING INFORMATION AND POLICIES**

**3.1** The accounting policies and methods of computation adopted in the preparation of these consolidated condensed interim financial statements are the same as those applied in the preparation of the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2024.

### **3.2 Restatement**

The Institute of Chartered Accountant of Pakistan (ICAP) has withdrawn the Technical Release 27 "IAS 12, Income Taxes (Revised 2012)" and issued guidance - "IAS 12 Application Guidance on Accounting for Minimum Taxes and Final Taxes" via circular No. 07/2024 dated May 15 2024. The said guidance requires certain amounts of tax paid under minimum and final tax regime to be shown separately as a levy instead of showing it in current tax.

Accordingly, the impact has been incorporated in these condensed interim financial statements retrospectively in accordance with the requirement of International Accounting Standard (IAS 8) - 'Accounting Policies, Change in Accounting Estimates and Errors'. This requirement was initially applied in the unconsolidated financial statements of the Company for the year ended June 30, 2024. Accordingly the figures of prior period condensed interim financial statement for the period ended March 31, 2024 have been restated. There has been no effect on the condensed interim statement of financial position, the condensed interim statement of changes in equity, the condensed interim statement of cash flows and earnings per share as a result of this change.

### **3.3 Changes in accounting standards, interpretations and pronouncements**

#### **a) Standards and amendments to approved accounting standards that are effective**

There are certain amendments and interpretations to the accounting and reporting standards which are mandatory for the Group's annual accounting period which began on July 1, 2024. However, these do not have any significant impact on the Group's financial reporting.

#### **b) Standards and amendments to approved accounting standards that are not yet effective**

There are certain standards, amendments and interpretations to the accounting and reporting standards that will be mandatory for the Group's annual accounting periods beginning on or after July 1, 2025. However, these will not have any impact on the Group's financial reporting and, therefore, have not been disclosed in these consolidated condensed interim financial statements except for the following:

## Notes to the Consolidated Condensed Interim Financial Statements

### For the period ended March 31, 2025 - Unaudited

The following standard and amendment are not effective for the accounting periods beginning on or after 1 January 2024 and have not been early adopted by the Group:

#### **Amendment to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments**

These amendments:

- clarify the requirements for the timing of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system;

clarify and add further guidance for assessing whether a financial asset meets the solely payments of principal and interest (SPPI) criterion;

add new disclosures for certain instruments with contractual terms that can change cash flows (such as some instruments with features linked to the achievement of environment, social and governance (ESG) targets); and

make updates to the disclosures for equity instruments designated at Fair Value through Other Comprehensive Income (FVOCI).

The management is in process of assessing the impact of above changes.

#### **4. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES**

The carrying values of all financial assets and liabilities reflected in these unconsolidated condensed interim financial statements approximate to their fair value.

#### **5. SIGNIFICANT ACCOUNTING INFORMATION AND POLICIES**

The accounting policies adopted in the preparation of these consolidated condensed interim financial statements are the same as those applied in the preparation of the annual financial statements of the Group for the year ended June 30, 2024.

#### **6. ACCOUNTING ESTIMATES, JUDGEMENTS AND FINANCIAL RISK MANAGEMENT**

The preparation of these consolidated condensed interim financial statements in conformity with approved accounting and reporting standards requires management to make estimates, assumptions and use judgements that affect the application of policies and reported amounts of assets and liabilities and income and expenses. Estimates, assumptions and judgements are continually evaluated and based on historical experience and other factors, including reasonable expectations of future events. Revisions to accounting estimates are recognised prospectively commencing from the period of revision.

Judgements and estimates made by the management in the preparation of this consolidated condensed interim financial information are the same as those that were applied to the annual audited consolidated financial statements as at and for the year ended June 30, 2024.

The Group's financial risk management objectives and policies are consistent with those disclosed in the annual audited consolidated financial statements as at and for the year ended June 30, 2024.

## Notes to the Consolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

	(Unaudited) March 31 2025	(Audited) June 30, 2024
	----- (Rupees in '000) -----	
<b>7. PROPERTY, PLANT AND EQUIPMENT</b>		
Operating assets - note 7.1	9,560,148	9,937,390
Capital work-in-progress - at cost	623,125	458,626
	<b>10,183,273</b>	<b>10,396,016</b>
<b>7.1 Additions - operating fixed assets (at cost)</b>		
Leasehold Land	-	4,817
Building on leasehold land	22,194	17,818
Plant and machinery	8,036	58,236
Office equipment	2,914	63,548
Furniture and fittings	1,342	1,054
Vehicles	-	2,799
Air conditioning systems	18,915	5,162
	<b>53,401</b>	<b>153,434</b>
<b>8. RIGHT-OF-USE ASSET</b>		
Opening net book value	63,982	60,090
Acquisition of subsidiaries	-	23,463
Addition	-	1,918
Depreciation for the period - note 8.1	(15,326)	(21,489)
Net book value as at	<b>48,656</b>	<b>63,982</b>
<b>8.1</b> Depreciation expense on right-of-use asset has been charged to cost of sales.		
<b>9. INTANGIBLES</b>		
Operating intangible assets	26,330	41,367
Goodwill - note 9.1	3,983,752	4,583,752
	<b>4,010,082</b>	<b>4,625,119</b>
<b>9.1</b> This represents goodwill pertaining to Nextar Pharma (Private) Limited, Searle Pakistan Limited and upon acquisition of subsidiaries.		

## Notes to the Consolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

	(Unaudited) March 31 2025	(Audited) June 30, 2024
	----- (Rupees in '000) -----	
<b>10 TRADE RECEIVABLES</b>		
Considered good		
- Export receivables, secured	975,786	420,577
- Due from related parties, unsecured	9,714,996	10,975,841
- Others, unsecured	1,937,339	1,289,340
	12,628,121	12,685,758
Less: Provision for doubtful receivables	(212,390)	(214,236)
	12,415,731	12,471,522
<b>11 LOANS AND ADVANCES - considered good</b>		
Advances to:		
Secured		
- employees for operating activities	205,378	111,566
- employees against salaries	36,145	12,348
Unsecured		
- advance to Universal Ventures (Private) Limited	4,909	4,468
- advance to associated companies	-	4,586
- suppliers	519,977	376,235
- against imports	102,341	157,622
- against LC margin	-	1,833
Other advances	117,290	4,996
Current portion of long-term loans to employee	104	142
	986,144	673,796



## Notes to the Consolidated Condensed Interim Financial Statements

### For the period ended March 31, 2025 - Unaudited

	(Unaudited) March 31 2025	(Audited) June 30, 2024
	------(Rupees in '000)-----	
<b>12 OTHER RECEIVABLES</b>		
<b>Receivables from related parties</b>		
Due from Ultimate Parent Company and associated companies:		
- International Brands (Private) Limited	88,817	62,486
- IBL Operations (Private) Limited	151,367	152,493
- Universal Ventures (Private) Limited	86,452	86,452
- Mywater (Private) Limited	-	3,560
- IBL Logistics (Private) Limited	-	1,692
- IBL Unisys (Private) Limited	4,311	88,326
	<b>330,947</b>	<b>395,009</b>
Due from other related party:		
- United Retail (SMC- Private) Limited	43,050	13,176
- Universal Retail (SMC- Private) Limited	267,520	182,754
	<b>310,570</b>	<b>195,930</b>
Surplus arising under retirement benefit fund	5,250	5,250
<b>Receivables from other than related parties</b>		
Noventa Pharma (Private) Limited against:		
Sale of subsidiary	3,726,753	-
Others, considered good	1,083,450	261,621
	<b>5,456,970</b>	<b>857,810</b>
<b>13. LONG-TERM BORROWINGS</b>		
<b>Islamic</b>		
Musharika Facility - note 13.1	-	3,695,769
Diminishing musharika	63,586	72,301
	<b>63,586</b>	<b>3,768,070</b>
<b>13.1</b>	The Parent Company obtained a musharaka facility from Habib Bank Limited (Musharaka Agent) for a period of 7 years with a repayment grace period of two years. The Parent Company is required to repay the amount of the loan in quarterly installments, starting from September 2022. This facility carries a mark-up of three months KIBOR plus 1.35%. The Parent Company has repaid the entire loan on January 30, 2025 to meet the requirement of Share Purchase Agreement along with an early payment fee of Rs. 49.43 million.	
<b>14. TRADE AND OTHER PAYABLES</b>		
Creditors & Accrued liabilities	5,418,484	5,476,720
Payable under group relief	21,418	21,418
Salaries and benefits payable	-	2,993
Bills payable in foreign currency	1,667,219	2,108,270
Payable to provident fund	156,303	103,765
Accrued markup	238,508	465,594
Workers' Profit Participation Fund	21,836	15,018
Workers' Welfare Fund	43,888	35,591
Other liabilities	244,432	169,279
	<b>7,812,088</b>	<b>8,398,648</b>

## Notes to the Consolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

March 31	March 31
2025	2024
------(Rupees in '000)-----	

### 15. SHORT-TERM BORROWINGS

#### Secured borrowings

##### Conventional:

Running finance under mark-up arrangements - note 15.1

1,284,992 1,293,150

##### Islamic:

Running musharaka - note 15.1

6,487,413 5,992,008

#### Unsecured borrowings

IBL Holding (Private) Limited

- 11,411

7,772,405 7,296,569

- 15.1** The Parent Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 7,650 million (June 30, 2024: Rs. 7,650 million) which include financing facilities obtained under Islamic mode amounting to Rs. 6,350 million (June 30, 2024: Rs. 6,350 million). The arrangements are secured jointly by registered mortgage of Rs. 1,937.5 million (June 30, 2024: Rs. 1,937.5 million) of immovable property together with a joint pari passu charge on all current assets of the Company to the extent of Rs. 11,095.83 million (June 30, 2024: Rs. 11,095.83 million).

- 15.1.1** The Parent Company's rates of mark-up ranged between 15.86% to 21.83% (June 30, 2024: 22.96% to 24.66%) per annum.

### 16. CONTINGENCIES AND COMMITMENTS

#### 16.1 Contingencies

There has been no significant change in the status of contingencies as reported in note 31 of annual audited consolidated financial statements of the Group for the year ended June 30, 2024.

#### 16.2 Commitments

- 16.2.1** The facility for opening letters of credit and guarantees of the Parent Company as at December 31, 2024 amounted to Rs. 2,750 million (June 30, 2024: Rs. 2,750 million) of which the amount remain unutilised as at period ended December 31, 2024 amounted to Rs. 1,309.89 million (June 30, 2024: Rs. 1,530.98 million).

- 16.2.2** The facility for opening Letters of Credit of IBL Healthcare Limited as at December 31, 2024 amounted to Rs. 800 million (June 30, 2024: Rs. 650 million) and Rs. 20 million (2024: Rs. 20 million) of which the amount remaining unutilised at the end of period was Rs. 311.74 million (June 30, 2024: Rs. 134 million) and Rs. 5.96 million (2024: Rs. 5.96 million) respectively.

## Notes to the Consolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

	March 31 2025	March 31 2024
------(Rupees in '000)-----		
<b>17. REVENUE FROM CONTRACT WITH CUSTOMERS</b>		
Gross sales		
Local sales	23,236,291	23,592,365
Export sales	2,125,731	1,819,917
	<u>25,362,022</u>	<u>25,412,282</u>
Toll manufacturing	2,408	2,146
	<u>25,364,430</u>	<u>25,414,428</u>
Sales tax	(554,812)	(303,930)
	<u>24,809,618</u>	<u>25,110,498</u>
Less:		
Discounts, rebates and allowances	(1,917,668)	(1,529,492)
Sales returns	(896,215)	(1,300,582)
	<u>(2,813,883)</u>	<u>(2,830,074)</u>
	<u>21,995,735</u>	<u>22,280,424</u>
<b>18. OTHER INCOME</b>		
<b>Income from financial assets</b>		
Interest income on Term Finance Certificate	14,595	17,741
<b>Income from non - financial assets</b>		
Gain on disposal of property, plant and equipment	-	1,490
Rental income from investment properties	68,111	66,563
Gain on disposal of property, plant and equipment	16,685	-
Scrap sales	23,969	25,426
Interest Income on Loan - Searle Pakistan Limited	147,963	-
Others	8,417	95,580
	<u>265,145</u>	<u>189,059</u>
	<u>279,740</u>	<u>206,800</u>
<b>19. BASIC AND DILUTED EARNINGS PER SHARE</b>		
		(Re-stated)
Profit for the period	(321,690)	(590,726)
Weighted average number of outstanding shares at the end of the period (in thousand)	511,494	511,494
Basic and diluted earnings per share (Rupees)	(0.63)	(1.15)

## Notes to the Consolidated Condensed Interim Financial Statements

For the period ended March 31, 2025 - Unaudited

	March 31 2025	March 31 2024
	------(Rupees in '000)-----	
<b>20. CASH GENERATED FROM OPERATIONS</b>		
Profit before income tax	82,077	(137,706)
<b>Add / (less): Adjustments for non-cash charges and other items</b>		
Depreciation on property, plant and equipment	605,738	579,178
Depreciation on investment property	77,409	57,876
Depreciation on right-of-use-asset	15,326	4,830
Amortisation	15,037	11,733
Gain on disposal of property, plant and equipment	(35)	571
Provision for retirement benefits obligation	10,477	10,317
Loss on disposal of subsidiary	1,450,124	-
Interest income	(5,505)	-
Finance cost	2,022,125	3,123,718
Interest on lease liability	6,112	13,456
Amortisation of transaction cost	18,424	12,636
Provision for doubtful receivable	-	10,100
Profit before working capital changes	4,297,309	3,686,709
<b>Effect on cash flow due to working capital changes</b>		
(Increase) / decrease in current assets		
Inventories	17,313	1,779,161
Trade receivables	(155,248)	(1,902,751)
Loans and advances	(473,044)	(1,038,555)
Trade deposits and short-term prepayments	(148,559)	(20,427)
Accrued markup	-	420
Tax refunds due from government - Sales tax	(2,783)	17,099
Other receivables	(872,407)	3,638,866
	(1,634,728)	2,473,813
Increase / (decrease) in current liabilities		
Trade and other payables	(1,365,888)	4,871,305
Contract liabilities	275,963	(40,367)
Cash generated from operations	1,572,656	10,991,460
<b>21. CASH AND CASH EQUIVALENTS</b>		
Cash and bank balances	277,563	242,645
Short term running finances - note 15	(7,772,405)	(9,701,910)
	(7,494,842)	(9,459,265)

## Notes to the Consolidated Condensed Interim Financial Statements

### For the preiod ended March 31, 2025 - Unaudited

#### 22. SEGMENT INFORMATION

Based on internal management reporting structure for the period, no reportable segments were identified that were of continuing significance for decision making.

#### 23. TRANSACTIONS WITH RELATED PARTIES

Disclosure of transactions between the Group and related parties

The related parties include the ultimate parent company, associated companies or undertakings, staff retirement funds, directors of the Group, key management personnel and key management personnel. The Group in the normal course of business carries out transactions with various related parties. The Group enters into transactions with related parties on the basis of mutually agreed terms. Significant transactions with related parties are as follows:

		March 31	March 31
		2025	2024
Nature of relationship		Nature of transactions	
		------(Rupees in '000)-----	
Ultimate parent company	- Corporate service charges	91,560	114,750
	- Rent income	14,896	13,345
	- Income from provision of amenities	11,435	10,723
	- Issuance of right shares	-	3,254,963
Associated companies	- Revenue	15,567,232	23,935,636
	- Salaries and wages	22,246	14,240
	- Purchases	-	7,245
	- Carriage and duties	203,512	183,592
	- Discounts claimed	434,444	546,693
	- Rent expense	72,797	61,368
	- Rent income	34,068	34,716
	- Stock claims	278,522	541,161
	- Internet services	5,046	8,608
	- Income from provision of amenities	118,461	85,833
	- Donations	35,574	49,808
	- Incentives to field force staff	18,298	4,493
	- Repair and maintenance	1,784	2,504
	- Merchandise expense	11,594	48,218
	- Others	5,610	33,966
	- Acquisition of subsidiaries	-	7,250,407
	- Reimbursement of expenses	33,861	-
Key management employees compensation	- Salaries and other employee benefits	285,300	228,578
	- Contributions to Provident Fund	20,474	21,815

23.1 The status of outstanding balances with related parties as at March 31, 2025, are included in the respective notes to the consolidated financial statements.

**Notes to the Consolidated Condensed Interim Financial Statements**  
For the period ended March 31, 2025 - Unaudited

**24. CORRESPONDING FIGURES**

Corresponding figures have been reclassified and re-arranged in these consolidated financial statements, wherever necessary, to facilitate comparison and to confirm with presentation in the current period, having insignificant impact.

**25. DATE OF AUTHORISATION FOR ISSUE**

This consolidated condensed interim financial information was approved and authorised for issue by the Board of Directors of the Parent Company on April 30, 2025.



Chief Executive



Director



Chief Financial Officer

The logo for Searle, featuring the word "SEARLE" in a bold, blue, sans-serif font. A thick blue vertical bar is positioned to the left of the text.

**THE SEARLE COMPANY LIMITED**

2nd Floor, One IBL Centre, Plot# 1, Block 7 & 8,  
Dehli Mercantile Muslim Cooperative Housing Society  
(DMCHS) Tipu Sultan Road, Off. Shahrah-e-Faisal, Karachi  
URL: [www.searlecompany.com](http://www.searlecompany.com)